RLAYRelay Therapeutics, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+4327.9% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$90M-903.0% margin

Net Income

-$81M-813.3% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

+1000800.0%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$52M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$841M

Total Liabilities

$96M

Stockholders' Equity

$746M

Cash & Equivalents

$153M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$226,000	+4327.9%
Gross Profit	$10M	-$83M	+112.1%
Operating Income	-$90M	-$101M	+10.7%
Net Income	-$81M	-$94M	+13.6%

RLAY Q1 2024 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena